Phase Ib/IIa Trial With AC01 in Patients With HFrEF
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled two-part study with a multiple
escalating dose phase followed by a cohort expansion phase to assess safety, tolerability,
pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced
ejection fraction (HFrEF).